Stay updated with breaking news from Abecma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from
By Colin Kellaher Bristol Myers Squibb Co. and 2seventy bio Inc. on Monday reported a trio of regulatory advances in their efforts to win approval for earlier use of their Abecma gene therapy... | April 17, 2023
Still ahead, more on the midterm elections including a closer look at the races that will determine control of the senate. which is a lot. so take care of that heart wiwith lipton. because sippin' on unsweetened lipton can help support a healthy heart. lipton.. stop chuggin'. start sippin'. moderate to severe eczema still disrupts my skin. despite treatment it disrupts my skin with itch. it disrupts skin with rash. but now, i can disrupt ecma with rinvoq. rinvoq is not a steroid, topical,r injection. it's one pill, once a day, that's effective without topical steroids. many taking rinvoq saw c...
Mexico's president has blasted Abbott as “dishonest” and “sensationalist."
Bristol Myers Squibb has data showing that its multiple myeloma treatment Abecma beat the standard of care, preliminary Phase 3 results that could support moving the FDA-approved CAR T-cell therapy into an earlier line of treatment—ahead of a rival cell therapy. In other BMS cell therapy news, the pharma giant started an R&D alliance focused on inflammatory bowel disease.